Vivos Therapeutics Inc Ordinary Shares VVOS
News
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment